An interventional study of Standard duodenal switch and Single-anastomosis duodenal switch in Obesity and Obesity, Morbid, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Laval University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.
Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2023, is one of 17 with no phase, and was the 27th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Ages 18–65
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–60 · Healthy volunteers
Laval University · Sites in Canada
Ages 18–60
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 151 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 57 across the 22 interventional studies, 145 across the 10 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 9 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05242835Laval UniversityManagement of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | 2027-01 |
| NCT05120492Nova Scotia Health AuthorityOptimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial | 2027-07 |
| NCT06002906University Health Network, TorontoThe Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery. | 2027-07-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity, Morbid with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.
Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.
With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 151 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient randomized for a the standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
Procedure: Standard duodenal switch
Patient randomized for a single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
Procedure: Single-anastomosis duodenal switch
Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
Also known as: BPD-DS
Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
Also known as: SADI
Excess weight loss
Percentage of excess weight loss mobilized in response to surgery
Time frame: 12 month
Peroperative complications
Complications graded with Clavien classification
Time frame: from baseline up to 60 months
Risk of malnutrition
Risk of malnutrition assessed through measurement of its risk being mild (albumin\<35g\\L), moderate (albumin\<30g/L) or severe (albumin\<25g/L)
Time frame: from baseline to 60 months
Change in quality of life (SF-36)
36-item short form survey evaluating quality of life on a scale form 0 to 100
Time frame: from baseline to 60 months
Change in quality of life (BAROS)
Bariatric Analyses and Reporting Outcomes System score form -7 to 9
Time frame: from baseline to 60 months
Change in quality of life (QLaval)
Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7
Time frame: from baseline to 60 months
Gastro-intestinal side effects
Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144
Time frame: from baseline to 60 months
Change in nutritional status (calcium)
Change in nutritional status based on blood analysis of calcium (mmol/L)
Time frame: from baseline to 60 months
Change in nutritional status (ferritin)
Change in nutritional status based on blood analysis of ferritin (ug/L)
Time frame: from baseline to 60 months
Change in nutritional status (TIBC)
Change in nutritional status based on blood analysis of TIBC (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (iron)
Change in nutritional status based on blood analysis of iron (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (prealbumin)
Change in nutritional status based on blood analysis of prealbumin (g/L)
Time frame: from baseline to 60 months
Change in nutritional status (transferrin)
Change in nutritional status based on blood analysis transferrin (g/L)
Time frame: from baseline to 60 months
Change in nutritional status (vitamin A)
Change in nutritional status based on blood analysis of vitamin A (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (vitamin D3)
Change in nutritional status based on blood analysis of vitamin D3 (nmol/L)
Time frame: from baseline to 60 months
Change in nutritional status (parathormone)
Change in nutritional status based on blood analysis parathormone (ng/L)
Time frame: from baseline to 60 months
Change in food intake
Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day)
Time frame: from baseline to 60 months
Change in eating behavior
Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15
Time frame: from baseline to 60 months
Change in food addiction
Change of eating behavior using the Yale Food Addiction Scale that includes a "symptom count" scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met
Time frame: from baseline to 60 months
Change in binge eating behavior
Change of eating behavior using the Binge Eating scale from 0 to 46
Time frame: from baseline to 60 months
Evolution of obesity related diseases
Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting
Time frame: from baseline to 60 months
Started Feb 2023 (actual). Primary completion is estimated for Jan 2027, 47 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 47 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.